Assessment of plasminogen activator inhibitor type 2 (PAI-2) as an imaging and therapeutic agent of human cancer by Hang, Minh-Thu Nguyen
University of Wollongong 
Research Online 
University of Wollongong Thesis Collection 
1954-2016 University of Wollongong Thesis Collections 
2001 
Assessment of plasminogen activator inhibitor type 2 (PAI-2) as an imaging 
and therapeutic agent of human cancer 
Minh-Thu Nguyen Hang 
University of Wollongong 
Follow this and additional works at: https://ro.uow.edu.au/theses 
University of Wollongong 
Copyright Warning 
You may print or download ONE copy of this document for the purpose of your own research or study. The University 
does not authorise you to copy, communicate or otherwise make available electronically to any other person any 
copyright material contained on this site. 
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, 
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe 
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court 
may impose penalties and award damages in relation to offences and infringements relating to copyright material. 
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the 
conversion of material into digital or electronic form. 
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily 
represent the views of the University of Wollongong. 
Recommended Citation 
Hang, Minh-Thu Nguyen, Assessment of plasminogen activator inhibitor type 2 (PAI-2) as an imaging and 
therapeutic agent of human cancer, Doctor of Philosophy thesis, Faculty of Science, University of 
Wollongong, 2001. https://ro.uow.edu.au/theses/1863 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 

ASSESSMENT OF PLASMINOGEN 
ACTIVATOR INHIBITOR TYPE 2 (PAI-2) AS 
AN IMAGING AND THERAPEUTIC AGENT 
OF HUMAN CANCER 
A thesis submitted in fulfilment of the requirements for the 
award of the degree 
PhD 
from 
UNIVERSITY OF WOLLONGONG 
by 
MINH-THU NGUYEN HANG, B.Sc.(Hons) 
DEPARTMENT OF BIOLOGICAL SCIENCES 
2001 
STATEMENT OF ORIGINALITY 
I, Minh-Thu N. Hang, declare that this thesis contains no material which has been 
accepted for the award of any degree or diploma in any University, and to the best of 
my knowledge contains no material which has been previously published or written 
by another person except where due reference is made in the text of this thesis. 
Minh-Thu N. Hang 
ACKNOWLEDGEMENTS 
My gratitude goes out to quite of a lot of people who have helped and supported me 
throughout my PhD. Thank-you to my supervisors Clive Bunn and Mark Baker for 
giving me an interesting project to work on and especially Clive, for sharing with me 
his enthusiasm for science. Thank-you to my two advisors Marie Ranson and Xiao-
Ming Liang for the guidance and technical assistance they provided. A special 
thanks to Marie for all the encouragement and positive attitude when experiments 
were not working. Thank-you to my friends from the Department of Biological 
Sciences and students from labll2 for their friendship and humour. Thank-you to 
Professor Rob Whelan, for his support and words of advice throughout. 
Special thanks to the people at Biotech Australia for all the PAI-2 preparations and 
numerous reagents and supplementing my PhD scholarship. Thank-you to Southern 
Pathology and the people in the Department of Histology at North WoUongong 
Hospital for histological sectioning and staining. 
Most importantly, the achievement of my PhD is due to the love and support from my 
family, Cha (dad), Me (mom), Quynh-Thu, Anh-Thu, and my husband, Michael. I am 
deeply greatful to my family for always being there for me and believing in me. 
Thank-you to Cha and Me, through the sacrifices they made to provide me a good 
education. Thank-you Michael for being so patient with all the late nights in the lab, 
the cranky moods and the instant noodle dinners and for proof reading this thesis. 
ABSTRACT 
The plasminogen activation cascade is an important proteolytic pathway involved in 
the growth and spread of cancer. Potentially, an inhibitor of plasminogen activation 
could make an excellent cancer imaging agent or cancer treatment. The aim of this 
thesis was to assess whether plasminogen activator inhibitor 2 (PAI-2) can image or 
treat colorectal cancer. The first part of this thesis examined the ability of PAI-2 to 
bind specifically to the human colorectal cancer cell line HCT116, These 
experiments involved confirmation of u-PA expression by HCT116 cells and cell 
binding studies with ^^ Î-PAI-2. The second part was examining the biodistribution 
and kinetics of '̂ ^I-PAI-2 in nude mice bearing tumour xenografts derived from 
HCT116 cells. The final part involved examining the effect PAI-2 treatment had on 
mice bearing HCTl 16 tumour xenografts. 
PAI-2 was found to bind specifically to u-PA on HCTl 16 cells. There appeared to be 
a high tumover rate of bound PAI-2 because it was difficult to detect ^^ Î-PAI-2/u-PA 
complexes by autoradiography. '̂ ^I-PAI-2 had a biphasic distribution in the 
bloodstream of control mice (distribution phase (Ti/2a) 12.5min, elimination phase 
(Ti/2p) 342min) and mice bearing tumour xenografts (Tyia 1.4min, Ti/2p 29min). 
Approximately 1% of I-PAI-2 localised to the tumour xenograft after a single 
intravenous injection. However, more '̂ ^I-PAI-2 could be localised to the tumour by 
multiple intravenous injections. From three separate therapy experiments with PAI-2, 
there did not appear to be any effect on relatively large tumours. However, in one 
iii 
experiment PAI-2 injections did cause two 1mm tumours to disappear. In conclusion, 
PAI-2 does bind to u-PA on HCTl 16 cells in vitro. In vivo, injected PAI-2 appeared 
unsuitable for the imaging of tumours or metastasis. However preliminary data from 
this thesis suggest that PAI-2 may have therapeutic potential against smaller tumours. 
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